Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation - PubMed (original) (raw)
doi: 10.1111/ajt.12540. Epub 2014 Jan 8.
A A Zachary, C M Magro, N M Desai, B J Orandi, N N Dagher, A L Singer, N Carter-Monroe, S M Nazarian, D L Segev, M B Streiff, R A Montgomery
Affiliations
- PMID: 24400968
- DOI: 10.1111/ajt.12540
Free article
Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation
B E Lonze et al. Am J Transplant. 2014 Feb.
Free article
Abstract
Renal transplantation in patients with antiphospholipid antibodies has historically proven challenging due to increased risk for thrombosis and allograft failure. This is especially true for patients with antiphospholipid antibody syndrome (APS) and its rare subtype, the catastrophic antiphospholipid antibody syndrome (CAPS). Since a critical mechanism of thrombosis in APS/CAPS is one mediated by complement activation, we hypothesized that preemptive treatment with the terminal complement inhibitor, eculizumab, would reduce the extent of vascular injury and thrombosis, enabling renal transplantation for patients in whom it would otherwise be contraindicated. Three patients with APS, two with a history of CAPS, were treated with continuous systemic anticoagulation together with eculizumab prior to and following live donor renal transplantation. Two patients were also sensitized to human leukocyte antigens (HLA) and required plasmapheresis for reduction of donor-specific antibodies. After follow-up ranging from 4 months to 4 years, all patients have functioning renal allografts. No systemic thrombotic events or early graft losses were observed. While the appropriate duration of treatment remains to be determined, this case series suggests that complement inhibitors such as eculizumab may prove to be effective in preventing the recurrence of APS after renal transplantation.
Keywords: Antibodies; coagulation; complement regulation; kidney transplantation.
© Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.
Similar articles
- Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T. Yamamoto T, et al. Transplant Proc. 2017 Jan-Feb;49(1):159-162. doi: 10.1016/j.transproceed.2016.10.013. Transplant Proc. 2017. PMID: 28104125 - Living donor renal transplantation in patients with antiphospholipid syndrome: A case report.
Choi JY, Jung JH, Shin S, Kim YH, Han DJ. Choi JY, et al. Medicine (Baltimore). 2016 Nov;95(46):e5419. doi: 10.1097/MD.0000000000005419. Medicine (Baltimore). 2016. PMID: 27861383 Free PMC article. - Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Tan EK, et al. Transplantation. 2019 Nov;103(11):2397-2404. doi: 10.1097/TP.0000000000002639. Transplantation. 2019. PMID: 30801549 Free PMC article. - Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Kello N, et al. Semin Arthritis Rheum. 2019 Aug;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005. Epub 2018 Dec 4. Semin Arthritis Rheum. 2019. PMID: 30598332 Review. - Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
Okumi M, Tanabe K. Okumi M, et al. Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Nephrology (Carlton). 2016. PMID: 26988663 Review.
Cited by
- Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Jacobs L, Wauters N, Lablad Y, Morelle J, Taghavi M. Jacobs L, et al. Antibodies (Basel). 2024 Mar 12;13(1):21. doi: 10.3390/antib13010021. Antibodies (Basel). 2024. PMID: 38534211 Free PMC article. Review. - Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome.
Frederick R, Zolio L, Romas E, Ierino F. Frederick R, et al. BMJ Case Rep. 2024 Mar 5;17(3):e254449. doi: 10.1136/bcr-2022-254449. BMJ Case Rep. 2024. PMID: 38442982 - Thrombotic microangiopathy due to primary antiphospholipid syndrome: successful treatment with eculizumab.
Pala C, Parenti E, Vizzini G, Gianfreda D, Rossi GM. Pala C, et al. J Nephrol. 2024 May;37(4):1141-1145. doi: 10.1007/s40620-023-01789-4. Epub 2023 Oct 17. J Nephrol. 2024. PMID: 37847369 - New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations.
Sakowicz A, Bralewska M, Rybak-Krzyszkowska M, Grzesiak M, Pietrucha T. Sakowicz A, et al. Int J Mol Sci. 2023 Jul 28;24(15):12100. doi: 10.3390/ijms241512100. Int J Mol Sci. 2023. PMID: 37569476 Free PMC article. Review. - An update on the biologics for the treatment of antiphospholipid syndrome.
Yun Z, Duan L, Liu X, Cai Q, Li C. Yun Z, et al. Front Immunol. 2023 May 19;14:1145145. doi: 10.3389/fimmu.2023.1145145. eCollection 2023. Front Immunol. 2023. PMID: 37275894 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous